Design, Synthesis, and Pharmacological Evaluation of Novel Quinolone Aryl Sulfonamide Derivatives as Potent GPR55 Antagonists †
by
,
Paula Morales
1,2,*
,
Laura Figuerola-Asencio
1,
Dow H. Hurst
2,
Pingwei Zhao
3,
Mary E. Abood
3,
Patricia H. Reggio
2 and
Nadine Jagerovic
1 1
Instituto de Química Médica, CSIC, Juan de la Cierva, 3, 28006 Madrid, Spain
2
Department of Chemistry and Biochemistry, UNC Greensboro, Greensboro, NC 27402, USA
3
Center for Substance Abuse Research, Department of Anatomy and Cell Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
*
Author to whom correspondence should be addressed.
†
Presented at the 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery, Barcelona, Spain, 15–17 May 2019.
Proceedings 2019, 22(1), 92; https://doi.org/10.3390/proceedings2019022092
Published: 2 September 2019
(This article belongs to the Proceedings of The 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery)
Abstract
:Docking studies of identified GPR55 ligands using a GPR55 inactive state model allow rationalizing key structural features involved in ligand–receptor binding. On this molecular basis, we have designed novel quinolone sulfonamide derivatives with optimized potency and efficacy. These novel molecules compounds are being synthesized and evaluated using a β-arrestin recruitment assay in CHO cells overexpressing human GPR55 and βarr2-GFP.
The orphan Class A G-protein-coupled receptor GPR55 has been proposed as a potential member of the cannabinoid receptor family. This receptor has been implicated in numerous physiopathological conditions, such as metabolic disorders, inflammatory and neuropathic pain, regulation of vascular functions, bone physiology, cancer, and motor coordination.
Diverse studies point towards the phospholipid LPI (lysophosphatidylinositol) as the endogenous ligand for GPR55. In addition, diverse chemical entities, endogenous, phytogenic, and synthetic cannabinoid ligands among them have been shown to modulate this receptor. Nonetheless, pharmacological inconsistencies and the lack of potent and selective GPR55 ligands are delaying the exploitation of such a promising therapeutic target.
In an effort to identify GPR55 ligands, a high-throughput, high-content screening discovered the quinolone aryl sulfonamide ML193 (CID1261822) as an antagonist of this receptor [1]. Using our GPR55 inactive state model [2,3], docking studies of this compound and its analogs helped us to rationalize key structural features involved in ligand–receptor binding. On this molecular basis, we have designed novel quinolone sulfonamide derivatives with optimized potency and efficacy. These novel molecules compounds are being synthesized and evaluated using a β-arrestin recruitment assay in CHO cells overexpressing human GPR55 and barr2-GFP.
In summary, we pursued a combination of structure–activity relationship development and molecular modeling studies to identify novel potent GPR55 antagonists that may serve as new tools for studying GPR55. [Support: NIH RO1 DA045698].
References
- Heynen-genel, S.; Dahl, R.; Shi, S.; Milan, L.; Hariharan, S.; Sergienko, E.; Hedrick, M.; Dad, S.; Stonich, D.; Su, Y.; et al. Screening for Selective Ligands for GPR55-Antagonists. Probe Reports from the NIH Molecular Libraries Program; National Center for Biotechnology Information (U.S.): Bethesda, MD, USA, 2010; Available online: http://www.ncbi.nlm.nih.gov/books/NBK66153/ (accessed on 12 August 2019).
- Kotsikorou, E.; Sharir, H.; Shore, D.M.; Hurst, D.P.; Lynch, D.L.; Madrigal, K.E.; Heynen-Genel, S.; Milan, L.B.; Chung, T.D.Y.; Seltzman, H.H.; et al. Identification of the GPR55 Antagonist Binding Site Using a Novel Set of High-Potency GPR55 Selective Ligands. Biochemistry 2013, 52, 9456–9469. [Google Scholar] [CrossRef] [PubMed]
- Lingerfelt, M.A.; Zhao, P.; Sharir, H.P.; Hurst, D.P.; Reggio, P.H.; Abood, M.E. Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor. Biochemistry 2017, 56, 473–486. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Morales, P.; Figuerola-Asencio, L.; Hurst, D.H.; Zhao, P.; Abood, M.E.; Reggio, P.H.; Jagerovic, N. Design, Synthesis, and Pharmacological Evaluation of Novel Quinolone Aryl Sulfonamide Derivatives as Potent GPR55 Antagonists. Proceedings 2019, 22, 92. https://doi.org/10.3390/proceedings2019022092
AMA Style
Morales P, Figuerola-Asencio L, Hurst DH, Zhao P, Abood ME, Reggio PH, Jagerovic N. Design, Synthesis, and Pharmacological Evaluation of Novel Quinolone Aryl Sulfonamide Derivatives as Potent GPR55 Antagonists. Proceedings. 2019; 22(1):92. https://doi.org/10.3390/proceedings2019022092
Chicago/Turabian StyleMorales, Paula, Laura Figuerola-Asencio, Dow H. Hurst, Pingwei Zhao, Mary E. Abood, Patricia H. Reggio, and Nadine Jagerovic. 2019. "Design, Synthesis, and Pharmacological Evaluation of Novel Quinolone Aryl Sulfonamide Derivatives as Potent GPR55 Antagonists" Proceedings 22, no. 1: 92. https://doi.org/10.3390/proceedings2019022092
